Twenty years translating biology into decisions
I founded MyMetabolome to bring senior-level scientific expertise directly to the organizations that need it — without the overhead of a large consultancy. My work sits at the intersection of lipid biology, multi-omics mass spectrometry, and translational drug development.
Over two decades I have built omics platforms and biomarker programs from the ground up at Denali Therapeutics and Arkuda Therapeutics, advancing assets through proof-of-concept in Alzheimer's, Parkinson's, lysosomal storage disorders, frontotemporal dementia, and neuroinflammation. A particular focus has been lysosomal trafficking and its role in brain disease — including progranulin biology, GBA-related lipid dysregulation, and sphingolipid pathway alterations connecting lysosomal dysfunction to neurodegeneration. I have led CRO partnerships, shaped regulatory-facing evidence packages, and presented at Scientific Advisory Board (SAB) meetings.
My expertise extends well beyond neuroscience. I have applied multi-omics approaches to metabolic disorders (insulin resistance, hepatic steatosis, cardiometabolic disease), inflammation and immune biology (oxylipins, eicosanoids, endocannabinoid system), and nutrition and food science — areas interconnected at the level of lipid biology and metabolic pathway dysregulation.
What sets my work apart is depth in lipid biology — one of the fastest-growing areas in drug discovery and precision medicine — combined with the strategic and leadership experience to translate that science into portfolio-level decisions.
I also hold an adjunct faculty position at Georgetown University, where I lead NIH- and Alzheimer's Association-funded research and mentor the next generation of translational scientists.
